BACKGROUND:

The involvement of the l-arginine/nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) pathway in antinociception has been implicated as a molecular mechanism of antinociception produced by several antinociceptive agents, including μ-, κ-, or δ-opioid receptor agonists, nonsteroidal analgesics, cholinergic agonist, and α 2C adrenoceptor agonist. In this study, we investigated whether ketamine, a dissociative anesthetic N-methyl-d-aspartate receptor antagonist, was also capable of activating the l-arginine/NO/cGMP pathway and eliciting peripheral antinociception.

METHODS:

The rat paw pressure test was used, with hyperalgesia induced by intraplantar injection of prostaglandin E 2. All drugs were locally administered into the right hindpaw of male Wistar rats.

RESULTS:

Ketamine (10, 20, 40, 80 μg/paw) elicited a local antinociceptive effect that was antagonized by the nonselective NOS inhibitor l-NOARG (12, 18, and 24 μg/paw) and by the selective neuronal NOS inhibitor l-NPA (12, 18, and 24 μg/paw). In another experiment, we used the inhibitors l-NIO and l-NIL (24 μg/paw) to selectively inhibit endothelial and inducible NOS, respectively. These 2 drugs were ineffective at blocking the effects of the peripheral ketamine injection. In addition, the level of nitrite in the homogenized paw indicated that exogenous ketamine is able to induce NO release. The soluble guanylyl cyclase inhibitor ODQ (25, 50, and 100 μg/paw) blocked the action of ketamine, and the cGMP-phosphodiesterase inhibitor zaprinast (50 μg/paw) enhanced the antinociceptive effects of low-dose ketamine (10 μg/paw).

CONCLUSIONS:

Our results suggest that ketamine stimulates the l-arginine/NO/cyclic GMP pathway via neuronal NO synthase to induce peripheral antinociceptive effects.